"Roche has filed an appeal against the Hon. Delhi High Court order and the matter is subjudice in the appeal court," Roche ...

Roche had appealed against a single judge order of March 24 that had refused to stop Natco Pharma from manufacturing a generic version of Risdiplam ...

In a major relief to Indian drugmaker Natco Pharma, the Delhi High Court has rejected an interim injunction plea filed by ...

The Delhi High Court denied Roche's request to temporarily restrain Natco Pharma from producing its spinal muscular atrophy ...

The bench said that public good outweighs the company’s profit as the drug is not available at an affordable price in India.

The Delhi High Court on Monday dismissed an interim injunction application filed by Swiss pharmaceutical giant F Hoffmann-La ...

The high court decision potentially opens the door for access to a generic version of the patented drug - Risdiplam - at a fraction of the cost marketed by the Swiss pharmaceutical major.

The high court noted that SMA is a debilitating disease which has no cure, and the only approved drug, Risdiplam, marketed ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Patients with Spinal Muscular Atrophy (SMA) are hopeful of getting access to generic versions of Roche’s patented drug ...